摘要
目的观察奥扎格雷对急性冠脉综合征(ACS)患者血浆可溶性白细胞分化抗原40配体(sCD40L)及金属蛋白酶-9(MMP-9)含量的影响。方法选择80例ACS病人,其中急性心肌梗死(AMI)40例,不稳定心绞痛(UAP)40例,随机分为治疗组(常规治疗加奥扎格雷,n=40)和对照组(常规治疗,n=40),分别测定治疗前后病人血浆sCD40L及MMP-9的含量,进行统计分析。结果两组病人治疗后的血浆sCD40L及MMP-9明显下降,奥扎格雷治疗组血浆sCD40L含量下降幅度(65%)大于对照组降低(47%);血浆MMP-9含量在治疗组的下降幅度(60%)也大于对照组(45%)。结论用奥扎格雷治疗ACS病人,能显著降低血清CD40L及MMP-9的含量。
[Objective] To observe the influence of azagral sodium to the plasma soluble CD4o ligand. （sCD40L） and matrix metalloprotease-9 （MMP-9） in patients with acute coronary syndrome （ACS）. [Methods] The subjects included 80 patients with ACS, in which 40 patients had acute myocardiol infarction （AMI） and 40 patients had unstable angina pectoris （UAP）. The patients were divided into two groups： treatment group and control group. There were 40 cases in each group, Plasma levels of sCD40L and MMP-9 were measured in all the patients before and after treatment with medcine. [Resulls] The plasma levels of sCD40L and MMP-9 in the treatment group were siginificantly reduced compared to that of the control group （P 〈0.05）. [Conclusion] With the treatment of azagral sodium in patients with ACS, the plasma levels of sCD40L and MMP-9 are remarkably inhibited.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2008年第4期473-475,共3页
China Journal of Modern Medicine
